MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

2Q 2024 Total revenues of $72M; +49$139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of$29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended June  ...